Prospective, controlled, randomized, monocentric clinical investigation of performance and safety of Pro-ophta® Ocular Sticks in comparison with an alternative device

Organizational Data

DRKS-ID:
DRKS00025690
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2021-11-16
Last update in DRKS:
2024-02-07
Registration type:
Prospective

Acronym/abbreviation of the study

No Entry

URL of the study

No Entry

Brief summary in lay language

Comparation study to evaluate the performance, safety and usability of the device Pro-ophta® Ocular Sticks and BVI Visitec® Absorbent Stick devices.

Brief summary in scientific language

Prospective, controlled, randomized, monocentric comparison study. The performance, safety and usability of the device Pro-ophta® Ocular Sticks and BVI Visitec® Absorbent Stick devices will be evaluated and compared. Patients, requiring an eye surgery, will be included and randomly divid-ed in two equal groups, with Pro-ophta® Ocular Sticks used during ocular surgery for one group and BVI Visitec® Absorbent Stick device for another. Only one visit (surgery day) is planned for each patient. No follow up is planned for this study.

Health condition or problem studied

ICD10:
H00-H59 - Diseases of the eye and adnexa
Healthy volunteers:
No

Interventions, Observational Groups

Arm 1:
Pro-ophta® Ocular Sticks
Arm 2:
BVI Visitec® Absorbent Stick

Endpoints

Primary outcome:
Performance of the product, measured by level of satisfaction of the surgeon
Secondary outcome:
Frequency and severity of device-related adverse events and incidents

Study Design

Purpose:
Other
Allocation:
Randomized controlled study
Control:
  • Other
Phase:
IV
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • Medical center Augentagesklinik am Spreebogen Berlin

Recruitment period and number of participants

Planned study start date:
2021-12-31
Actual study start date:
2022-02-11
Planned study completion date:
No Entry
Actual Study Completion Date:
2023-02-28
Target Sample Size:
108
Final Sample Size:
106

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
Age ≥ 18 years Patient is legally capable Ophthalmology surgery is performed for a patient Patient has signed a written Informed Consent

Exclusion Criteria

Known intolerability to the product Participation in other clinical study within 30 days for the study entry and during the study Patient not covered by health insurance/social security

Addresses

Primary Sponsor

Address:
Lohmann & Rauscher GmbH & Co. KG
Angela Odame
Irlicher Str. 55
56567 Neuwied
Germany
Telephone:
+49 (0) 2631 99 6455
Fax:
49 (0) 2631 99 1455
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.lohmann-rauscher.com/de-de/
Investigator Sponsored/Initiated Trial (IST/IIT):
No

Contact for Scientific Queries

Address:
Augentagesklinik am Spreebogen
Dr. Prof. Manfred R. Tetz
Alt-Moabit 101 B
10559 Berlin
Germany
Telephone:
+49(30) 398098 – 0
Fax:
+49(30) 398098 – 44
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.augentagesklinik-spreebogen.de

Contact for Public Queries

Address:
Augentagesklinik am Spreebogen
Stefanie König
Alt-Moabit 101 B
10559 Berlin
Germany
Telephone:
10117
Fax:
+49(30) 398098 – 0
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.augentagesklinik-spreebogen.de

Principal Investigator

Address:
Augentagesklinik am Spreebogen
Dr. Prof. Manfred R. Tetz
Alt-Moabit 101 B
10559 Berlin
Germany
Telephone:
+49(30) 398098 – 0
Fax:
+49(30) 398098 – 44
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.augentagesklinik-spreebogen.de

Other contact for public queries

Address:
Lohmann & Rauscher GmbH & Co. KG
Dr Martin Abel
Irlicher Straße 55
56567 Neuwied
Germany
Telephone:
+49 (0) 2631 99 6566
Fax:
+49 (0) 2631 99 1566
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.lohmann-rauscher.com/de-de/

Sources of Monetary or Material Support

Commercial (pharmaceutical industry, medical engineering industry, etc.)

Address:
Lohmann & Rauscher GmbH & Co. KG
Irlicher Str. 55
56567 Neuwied
Germany
Telephone:
+49 2631 99-6566
Fax:
+49 2631 99-1566
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.lohmann-rauscher.com/de-de/

Ethics Committee

Address Ethics Committee

Address:
Ethik-Kommission der Ärztekammer Berlin
Friedrichstraße 16
10696 Berlin
Germany
Telephone:
(+49)30-408062601
Fax:
(+49)30-408062298
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2021-08-19
Ethics committee number:
Eth-57/21
Vote of the Ethics Committee:
Approved
Date of the vote:
2021-09-28

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
Q2 2024
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
106 patients (Pro-ophta® Ocular Stick , n = 53 and alternative device, n = 53) were included in the analyses. In both treatment groups, the investigator ́s/surgeon’s general user satisfaction was rated as either “good” or “very good”. The non-inferior hypothesis that the Pro-ophta® Ocular Stick is not rated worse in satisfaction than the alternative device was confirmed. Better/ higher judgement/satisfaction was observed when using the Pro-ophta® Ocular Stick and this effect was statistically significant (p = 0.0005). No device-related adverse event occurred. At least 98.12% were rated as “good” and “very good” in both treatment groups for the additional endpoints. No additional endpoint was rated worse than "rather good/satisfactory" (score of 3) on the 6-point Likert scale. However, better assessments were recorded when using Pro-ophta® Ocular Stick regarding all the additional endpoints except one: usage convenience (removal of foreign matter / dissecting out) with comparable evaluation in both treatment groups.